The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥ 65) patients with acute myocardial infarction without hypertension

[1]  M. Jeong,et al.  The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension , 2020, PloS one.

[2]  M. Jeong,et al.  Comparison of clinical outcomes between angiotensin-converting-enzyme inhibitors and ARBs in patients with acute myocardial infarction with dyslipidemia after a successful stent implantation , 2020, Anatolian journal of cardiology.

[3]  J. Ferrières,et al.  Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry , 2018, European journal of preventive cardiology.

[4]  M. Jeong,et al.  Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention. , 2018, Atherosclerosis.

[5]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[6]  M. Jeong,et al.  Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention. , 2017, International journal of cardiology.

[7]  S. Bangalore,et al.  Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction. , 2017, Circulation.

[8]  I. Komuro,et al.  Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. , 2014, The American journal of cardiology.

[9]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[10]  F. McAlister.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. , 2012, European heart journal.

[11]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[12]  Hani Jneid,et al.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c , 2011, Journal of the American College of Cardiology.

[13]  A. Boersch-Supan,et al.  Population Aging: Facts, Challenges, and Responses , 2011 .

[14]  K. Reynolds,et al.  Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension: A Meta-Analysis , 2012 .

[15]  J. Senges,et al.  The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction , 2010, Heart.

[16]  A. Coates,et al.  Angiotensin-converting enzyme-related cough among Chinese-Americans. , 2010, The American journal of medicine.

[17]  C. Kramer,et al.  Mechanisms of Post-Infarct Left Ventricular Remodeling. , 2007, Drug discovery today. Disease mechanisms.

[18]  A. Hall,et al.  Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox , 2006, Circulation.

[19]  S. Solomon,et al.  The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). , 2006, Journal of the American College of Cardiology.

[20]  Thomas E. Moritz,et al.  Coronary-artery revascularization before elective major vascular surgery. , 2004, The New England journal of medicine.

[21]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[22]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[23]  D. Hackam.  ACE inhibition in stable coronary artery disease. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[25]  E. Grech,et al.  Percutaneous coronary intervention. II: The procedure , 2003, BMJ : British Medical Journal.

[26]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[27]  A. Bignamini,et al.  Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. , 1999, American journal of hypertension.

[28]  L. Køber,et al.  Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension , 1997 .

[29]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[30]  J. Mehilli,et al.  [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.